Takeda’s narcolepsy strategy goes beyond drug development. The company is working with academic sleep researchers, clinical centers, medical experts and digital-health companies to better understand narcolepsy, improve diagnosis and develop treatments that target the underlying biology of narcolepsy type 1 (NT1).
Understand Where Companies Are Moving, What They Are Developing And What Buyers Need. Contact us today: https://www.towardshealthcare.com/contact-us
The centerpiece is oveporexton (TAK-861), an oral orexin-2 receptor agonist designed to restore orexin signaling. In 2026, oveporexton received regulatory approvals in Japan and the U.S., making Takeda’s collaboration network particularly relevant to the transition from research into clinical use.
Key Takeda Narcolepsy Collaborations
| Partner / organization | Collaboration focus | Why it matters |
|---|---|---|
| Stanford Center for Sleep Sciences and Medicine | Clinical research, orexin science and Phase 3 studies | Connects Takeda with leading narcolepsy expertise |
| Emmanuel Mignot / Stanford | Clinical research and scientific expertise | Mignot is a leading researcher in narcolepsy and orexin biology |
| University of Montpellier / INSERM | Clinical research and narcolepsy expertise | Supports international clinical development |
| National Reference Network for Narcolepsy, France | Patient research and clinical studies | Strengthens understanding of NT1 |
| Osaka Kaisei Hospital | Sleep medicine research and clinical studies | Adds Japanese clinical expertise |
| Leiden University Medical Center | International clinical research | Supports multinational evidence generation |
| Beacon Biosignals | Wearable brain-activity monitoring | Explores longitudinal, at-home measurement of narcolepsy |
| EnsoData | AI-based polysomnography algorithms | Aims to improve scalable and accurate NT1 diagnosis |
Takeda itself says it works with 200+ active collaborations globally, has around 100 public-private partnerships across 76 countries, and that more than 60% of its pipeline is partnered. These figures cover Takeda’s broader R&D organization, not narcolepsy specifically.
1. Stanford: One of the Most Important Academic Relationships
Stanford’s Center for Sleep Sciences and Medicine has been closely involved in Takeda’s orexin research.
The relationship includes clinical studies of TAK-861/oveporexton, including the First Light Phase 3 program. Stanford’s clinical-trial listing identifies TAK-861 as an OX2R agonist designed to restore orexin signaling in NT1.
Stanford researchers were also involved in earlier Takeda orexin studies.
A 2022 PNAS publication involving Takeda and Stanford researchers investigated an OX2R agonist in both a mouse model and humans with narcolepsy.
Why Stanford matters
The collaboration combines:
Basic orexin science + sleep medicine + clinical trials + patient assessment
This is important because narcolepsy is a complex neurological disorder requiring more than a conventional symptom-based drug-development approach.
2. Emmanuel Mignot and the Orexin Research Connection
Dr. Emmanuel Mignot of Stanford is one of the most prominent researchers in narcolepsy.
His work has been central to understanding the biological role of orexin in NT1, and he served as a key investigator in Takeda’s clinical development program.
The 2025 Phase 2b publication of oveporexton in the New England Journal of Medicine included investigators from Stanford and multiple international sleep centers. The trial enrolled 112 participants, with 90 receiving oveporexton and 22 receiving placebo.
The study showed improvements in:
- Wakefulness
- Excessive daytime sleepiness
- Cataplexy
- Overall narcolepsy symptoms
For example, the Epworth Sleepiness Scale improved by as much as 13.8 points at week 8 in one treatment group versus 2.5 points with placebo.
3. International Sleep-Medicine Research Network
Takeda’s development program is not dependent on a single institution.
The Phase 2b and Phase 3 research involved specialists from institutions across:
- United States
- France
- Italy
- Switzerland
- Netherlands
- Japan
- Spain
The NEJM publication included 22 authors and 13 institutional affiliations, demonstrating the international nature of the clinical research network.
The Phase 3 First Light program also involved leading sleep specialists including investigators from Stanford, Pitié-Salpêtrière University Hospital, University of Modena and Reggio Emilia, Vithas Hospitals, Leiden University Medical Center and Osaka Kaisei Hospital.
4. Beacon Biosignals: Moving Diagnosis Beyond the Sleep Lab
Takeda is also working with Beacon Biosignals on wearable technology.
The objective is to evaluate a wearable headband capable of remotely monitoring brain activity at home.
This could potentially provide:
- More frequent sleep data
- Longitudinal monitoring
- Real-world symptom information
- Additional information beyond a single overnight sleep study
Takeda says the collaboration is currently focused on applicability in the U.S.
This is strategically important because narcolepsy symptoms can vary substantially over time.
5. EnsoData: Applying AI to Sleep Diagnosis
Takeda is also collaborating with EnsoData to co-develop and validate AI-based polysomnography algorithms as diagnostic aids for NT1.
The goal is to identify subtle narcolepsy signatures that may be difficult to detect or interpret using conventional sleep-study approaches.
This represents a shift from simply developing a treatment toward improving the diagnostic pathway itself.
6. Patient and Clinical Community Involvement
Takeda’s broader narcolepsy development work has involved clinical-trial participants, patient advocacy organizations and academic partners.
The company has described its development effort as involving thousands of Takeda employees alongside these external stakeholders.
This matters because narcolepsy can remain underdiagnosed or misdiagnosed, and understanding patient experiences is important for improving diagnosis and treatment pathways.
What the Collaboration Network Is Trying to Solve
| Challenge | Takeda’s collaborative approach |
| Underlying disease biology | Orexin research |
| Treatment development | OX2R agonist clinical trials |
| Diagnosis | AI-enabled PSG |
| Longitudinal monitoring | Wearable brain-activity technology |
| Clinical evidence | International sleep centers |
| Patient experience | Patient and advocacy engagement |
| Global evidence | Multinational clinical programs |
The Clinical Evidence Behind the Partnerships
The collaboration strategy has produced substantial clinical-development data.
In two pivotal Phase 3 studies, Takeda reported that oveporexton met all primary and secondary endpoints, with statistically significant improvements across evaluated NT1 symptoms.
At SLEEP 2026, Takeda reported additional improvements in:
- Daily functioning
- Cognition
- Nighttime sleep
- Overall quality of life
Takeda also reported that 97% of treated participants reported improvement on the Patient Global Impression of Change measure in its Phase 3 program.
In August 2026, Japan approved ORZEYFUL (oveporexton) for adults with NT1, following earlier regulatory milestones.
Who Benefits From These Collaborations?
The ecosystem includes several important stakeholders:
Patients: Better diagnosis, monitoring and treatment options.
Sleep specialists: Improved diagnostic tools and new treatment approaches.
Hospitals and sleep centers: More advanced clinical protocols and evidence.
Researchers: Access to clinical data and new opportunities to study orexin biology.
Digital-health companies: Opportunities to develop technologies around sleep monitoring and diagnosis.
Pharmaceutical companies: New approaches for translating neuroscience research into therapies.
What Makes Takeda’s Approach Different?
Takeda’s strategy is increasingly connecting drug discovery with diagnostic innovation.
Instead of focusing exclusively on a medicine, the company is exploring:
Orexin biology → drug development → clinical trials → AI diagnosis → wearable monitoring → patient outcomes
That could become particularly important as narcolepsy care moves toward earlier diagnosis and more personalized treatment.
The Strategic Takeaway
Takeda’s narcolepsy collaborations show how modern neuroscience development increasingly depends on academic expertise, clinical networks and technology partnerships.
The strongest examples include Stanford’s sleep research ecosystem, international clinical centers, Beacon Biosignals’ wearable technology and EnsoData’s AI-based sleep analysis.
The bigger strategic question is:
Can pharmaceutical companies improve treatment outcomes by building partnerships around the entire patient journey; not just the drug?
Takeda’s narcolepsy program provides a strong example of this model, combining orexin science, clinical research, AI, wearable monitoring and patient-focused evidence generation.
What Towards Healthcare Offers You?
Towards Healthcare Research & Consulting can help pharma and biotech companies track R&D collaborations, academic partnerships, clinical trials, digital-health partnerships, patient organizations, drug pipelines, regulatory milestones and competitor strategies across neuroscience and rare-disease markets.
Connect with us for complete guidance or further enquiry at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium